PD 0325901
description
Additional Information
Applications:
|
FA
|
Synonyms:
|
PD-0325901, ZINC03938683, NCGC00189075-01, (R)-N-(2,3-Dihydroxypropoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide
|
Formulation:
|
Crystalline solid
|
Chemical Name:
|
N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide
|
Molecular Formula:
|
C16H14F3IN2O4 |
Molecular Weight: |
482.2
|
CAS Number
|
391210-10-9
|
Purity:
|
≥98%
|
Storage Conditions:
|
Product should be kept at -20°C.
|
References:
|
Sebolt-Leopold, J. S., Merriman, R., Omer, C., Tecle, H., Bridges, A., Klohs, W., ... & Leopold, W. R. (2004). The biological profile of PD 0325901: A second generation analog of CI-1040 with improved pharmaceutical potential. Cancer Research, 64(7 Supplement), 925-925. Haura, E. B., Ricart, A. D., Larson, T. G., Stella, P. J., Bazhenova, L., Miller, V. A., ... & Gadgeel, S. M. (2010). A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non–small cell lung cancer. Clinical Cancer Research, 16(8), 2450-2457. Leyton, J., Smith, G., Lees, M., Perumal, M., Aigbirhio, F. I., Golovko, O., ... & Aboagye, E. O. (2008). Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. Molecular cancer therapeutics, 7(9), 3112-3121. |